CD24 and colorectal carcinoma: Similarly, there was a progressively increasing trend in ANKRD22 expression during the progression from normal colorectal epithelium to inflammatory bowel disease (IBD) to CRC (Figure S1D). We also analyzed the expression of ANKRD22 in CCICs enriched by FACS based on CD24+CD44+ markers, treatment with chemotherapeutic drugs, in serum-free medium with low-adherence, and organoid culture.